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Background: Improper medication adherence is associated with increased morbidity, healthcare costs, and fracture
risk among patients with osteoporosis. The objective of this study was to evaluate the healthcare utilization
patterns of Medicare Part D beneficiaries newly initiating teriparatide, and to assess the association of medication
adherence and persistence with bone fracture.
Methods: This retrospective cohort study assessed medical and pharmacy claims of 761 Medicare members
initiating teriparatide in 2008 and 2009. Baseline characteristics, healthcare use, and healthcare costs 12 and 24
months after teriparatide initiation, were summarized. Adherence, measured by Proportion of Days Covered (PDC),
was categorized as high (PDC ≥ 80%), moderate (50% ≥ PDC < 80%), and low (PDC < 50%). Non-persistence was
measured as refill gaps in subsequent claims longer than 60 days plus the days of supply from the previous claim.
Multivariate logistic regression evaluated the association of adherence and persistence with fracture rates at 12
months.
Results: Within 12 months of teriparatide initiation, 21% of the cohort was highly-adherent. Low-adherent or
non-persistent patients visited the ER more frequently than did their highly-adherent or persistent counterparts
(χ2 = 5.01, p < 0.05 and χ2 = 5.84, p < 0.05), and had significantly lower mean pharmacy costs ($4,361 versus $13,472
and $4,757 versus $13,187, p < 0.0001). Furthermore, non-persistent patients had significantly lower total healthcare
costs. The healthcare costs of highly-adherent patients were largely pharmacy-related. Similar patterns were
observed in the 222 patients who had fractures at 12 months, among whom 89% of fracture-related costs were
pharmacy-related. The regression models demonstrated no significant association of adherence or persistence with
12-month fractures. Six months before initiating teriparatide, 50.7% of the cohort had experienced at least 1 fracture
episode. At 12 months, these patients were nearly 3 times more likely to have a fracture (OR = 2.9, 95% C.I. 2.1-4.1
p < 0.0001).
Conclusions: Adherence to teriparatide therapy was suboptimal. Increased pharmacy costs seemed to drive greater
costs among highly-adherent patients, whereas lower adherence correlated to greater ER utilization but not to
greater costs. Having a fracture in the 6 months before teriparatide initiation increased fracture risk at follow-up.
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Osteoporosis is a breakdown and weakening of the
bones that affects over 10 million individuals in the U.S.
and is linked to increased morbidity, mortality, and
healthcare costs [1,2]. Effective medications have been
developed to treat osteoporosis, but adherence to treat-
ment is suboptimal [3-5]. Proper adherence may delay
and prevent fracture, future bone loss, and other nega-
tive health outcomes [6,7]. After one year of therapy,
many patients discontinue or decrease dosages of daily
oral and injectable medications [7]; this non-persistence
and underuse may reduce the drugs’ effectiveness, pla-
cing patients at increased risk of fractures and other
negative outcomes [1,4,7].
Adherence and persistence with prescribed medication
are extremely important for patients at high risk for frac-
tures since these patients are at a much greater risk for
fractures relative to patients with mild to moderate
osteoporosis. Available studies suggest that reasons for
patients’ suboptimal adherence or persistence with
osteoporosis medications include concerns about side
effects, inconvenience of drug regimens, and drug costs
[8,9]. Drug cost concerns are of greater relevance to
patients who are prescribed injectable medications be-
cause these medications tend to be more costly than oral
agents. A recent prospective observational study of
patients taking teriparatide, a daily injectable drug devel-
oped to treat patients who are at high risk for fractures
or for whom first-line treatments have been ineffective
[10], found that patients who discontinued therapy
within 12 months did so primarily due to problems with
paying for prescriptions and perceptions that the bene-
fits of the treatment were outweighed by their concerns
about the treatment [11].
The cost sharing attributes of the Medicare Part D
prescription drug plan may pose a financial challenge to
patients with osteoporosis, especially to those taking
costlier medications [12]. Medicare Part D is a part of
Medicare, which is a U.S. government-sponsored health
insurance that provides coverage primarily for adults
over the age of 65. In Medicare Part D, government pay-
ments for drug purchases stop when a beneficiary
reaches an annual spending limit. Thereafter, beneficiar-
ies must pay for 100% of their prescription costs until
their out-of-pocket costs reach a pre-specified threshold
(catastrophic coverage) [12,13]. Patients taking costly
medications for chronic conditions such as osteoporosis
may reach this spending limit sooner, and as a conse-
quence, they may resort to cost-coping behaviors to
manage their healthcare spending during the resulting
gaps in coverage [14-17]. Some studies of Medicare Part
D patients have identified cost-coping strategies such as
using medications less frequently than prescribed, dis-
continuing medications, not filling prescriptions, andswitching to less expensive agents [18-20]. Other studies
suggest that cost-related responses are more common
among patients who have better knowledge of their ben-
efits and who report fewer financial burdens [21,22].
With regard to teriparatide use among Medicare benefi-
ciaries, one study posits that patients’ experiences with
the drug affect their healthcare spending habits and their
adherence during gaps in coverage [23].
In a recent retrospective cohort study, Tamariz and
colleagues evaluated patient persistence with teriparatide
and other osteoporosis medications as compared to per-
sistence with biologic therapies used to treat rheumatoid
arthritis (RA) and multiple sclerosis (MS) [12]. The
authors compared the pharmacy claims of health plan
members who had Medicare Part D prescription plans
with and without coverage gaps. The findings indicated
that patients taking osteoporosis medications, particu-
larly teriparatide, were more likely to discontinue taking
their medication if they reached the coverage gap,
whereas no such association was observed for patients
taking medications to treat RA or MS. A limitation of
this study was that it did not assess the medical and eco-
nomic outcomes associated with these persistence pat-
terns. In another retrospective cohort study, Yu and
colleagues evaluated the pharmacy and medical claims
of new teriparatide users aged 18 years and older [6].
The authors found that patients’ optimal adherence was
associated with a reduced risk of fractures at 6, 12 and
18 months following teriparatide initiation. This study
did not specifically assess fracture outcomes among
Medicare part D beneficiaries [6].
In order to address gaps noted in previous research,
the present study evaluated outcomes associated with
adherence and persistence among Medicare Part D
beneficiaries. This retrospective investigation was con-
ducted on a cohort of Medicare Advantage with Pre-
scription Drug coverage (MAPD) members who had
initiated prescriptions for teriparatide in 2008 and 2009
and who were enrolled through a large national health-
care provider. The study evaluated the outcomes of frac-




Figure 1 depicts the attrition diagram which identifies
how many health plan members were removed from the
sample due to the specified exclusion/inclusion criteria.
A total of 2,688 health plan members were enrolled in
the Medicare Advantage Plan between January 1, 2008
and December 31, 2009 and were identified as receiving
a prescription for teriparatide. Most of those identified
were excluded because they were not naïve to teriparatide
during the identification period, were not continuously
Enrolled in a Medicare Advantage Plan and Received a Claim for 
teriparatide Between 1/1/2008 and 12/31/2009
(n=2,688)
Eligible members with at least 18 months of continuous eligibility
(n=1,735) 





Less Than 6 Months of Continuous Eligibility (Pre-Period) (n=493)
Less Than 12 Months of Continuous Eligibility (Post-Period) (n=473)
< 18 or ≥ 90 Years Old on Index Date (n=112)
Excluded Members:
Enrolled in a Line of Business* to be Excluded During the Observation   
Period (n=212)
Low Income Subsidy During 18 Month Observation Period (n=560)  
Excluded Members:
Pharmacy Claim for teriparatide in the Pre-Index Period (n= 291) 
Figure 1 Sample attrition. *Line of Business = Type of health insurance coverage.
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months post index, and/or were eligible for the low income
subsidy (LIS) benefit program. The Final Study Group was
comprised of 761 members, 36% of which (272 members)
had 24 months of continuous post-period eligibility.
Patient characteristics
Table 1 depicts the baseline demographic characteristics
of the final sample (n = 761). The average age of patients
was 73 ± 8.4 years, and approximately 66% of the sample
was 70 years of age or older. Of the total sample, 88.7%
were female, and 93.4% were Caucasian. Participants
were primarily from the Southern and Midwestern Uni-
ted States (approximately 66% and 21%, respectively).
Table 2 summarizes the clinical characteristics of the
patient cohort and the percentages of patients who
reached the Medicare Part D coverage gap in the 12
months following initiation of teriparatide. At baseline,the Deyo-Charlson score for the group was relatively
low (mean of 1.1) indicating a low level of significant
comorbidities. The top three most prevalent comorbid-
ities were other disorders of bone and cartilage (ICD-9
code 733.xx; 98.8%), essential hypertension (ICD-9 code
401.xx; 71.7%), and disorders of lipid metabolism (ICD-9
code 272.xx; 69.5%). With regard to the use of osteopor-
osis drug therapy in the 6 month ‘pre’ period, 46.4% of
the cohort (353 patients) had used an osteoporosis
medication. Among these users, the most frequently
used medications were bisphosphonates (80%), calci-
tonin (11%), selective estrogen receptor modulator
(11%), and conjugated estrogen (6%). With respect to
prior fractures, 50.7% of the sample (386 patients) had
experienced a fracture during the 6 months before initiation
of teriparatide. In the 12-months following initiation of teri-
paratide, 77% of the sample (586 patients) had experienced
a gap in Medicare Part D prescription drug coverage.
Table 1 Demographic characteristics
Characteristic Count
Total Patients 761
Age, years (Mean, Standard Deviation) 73.3 (±8.4)
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period
Overall resource utilization in the 12 and 24-month
period following teriparatide initiation is summarized in
Table 3. In the 12-month post period, approximately
21% of the study group had at least 1 hospitalization,
31% had at least one emergency room (ER) visit, 99.9%
had at least one outpatient visit, and all members had at
least one pharmacy claim. In the subgroup of members
with 24 months of post-period follow-up (i.e., members
with coverage for months 1-24 following teriparatide ini-
tiation; n = 272), 31% had at least 1 hospitalization, more
than 44% had ER visits, and all members had at least
one outpatient visit and at least one pharmacy claim. As
noted in Table 3, the mean total healthcare costs
(plan paid and member share combined) amounted to
$17,460 per member at 12 months follow-up. At 24
months the costs were $30,292 per member. Inpatient
hospitalization costs were on average $4,585 (26%) at 12
months and $8,978 (29%) at 24 months. Outpatient costs
were $5,713 (33%) at 12 months and $9,673 (32%) at 24
months. Pharmacy costs allocated to the average mem-
ber amounted to $6,762 (39%) at 12 months and $10,787
(36%) at 24 months.
Fracture-related costs (plan cost and member share)
are summarized in Table 4 for members identified ashaving a fracture during the 12- or 24-month post peri-
ods (222 and 134 members, respectively). The mean
total fracture-related direct costs were $6,198 per mem-
ber at 12 months (i.e., months 1 to 12), and $8,389 per
member at 24 months of follow-up (i.e., months 1 to
24). ER-related costs were, on average, $35 at 12 months
and almost triple that amount at $100 at 24 months. In
contrast, inpatient hospitalization costs were, on average,
$1,123 at 12 months, and were $967 at 24 months. Mean
outpatient costs were $829 at 12 months and $1,007 at
24 months. The average osteoporosis medication pre-
scription costs allocated to each member amounted to
$3,965 at 12 months and $6,061 at 24 months. Pharmacy
costs for acute fracture treatment (pain medication)
were close at both time periods at $246 per member at
12 months, and $253 per member at 24 months.
Description of teriparatide adherence, persistence and
economic outcomes
In order to describe the manner in which adherence and
persistence with teriparatide therapy were related to eco-
nomic outcomes, patients were grouped according to their
adherence to the drug during the 12-month follow-up
period, and whether they persisted with therapy during
the same time frame (see Table 5). Adherence status was
reported as high (PDC ≥80%), moderate (50% ≤ PDC <
80%), and low (PDC < 50%). Persistence with teriparatide
was described as either ‘non-persistent’ or ‘persistent’ with
treatment. For each of the defined groups, the overall and
fracture-related utilization and costs were calculated. Chi
Square analyses, ANOVA pairwise comparisons, and
t-tests were used to assess significant differences in health-
care utilization and costs depending on patients’ adher-
ence or persistence groupings.
Teriparatide adherence/persistence and fracture-related
resource utilization - one year post index
The results in Table 5 show that of the entire cohort,
21% (163 patients) were highly adherent (PDC ≥ 80%) to
their teriparatide therapy, and 24% (181 patients) per-
sisted with taking the medication during the 12 month
follow-up period. In addition, the results indicate that
for the entire sample, there were significant differences
in patients’ ER visits, total healthcare costs, and phar-
macy costs depending on patients’ adherence or persist-
ence. With regard to healthcare resource utilization, Chi
Square test results revealed that there were significant
differences in the number of members with ER visits de-
pending on how adherent members were or whether or
not they were persistent with therapy. Patients who fell
into the low-adherence category (PDC < 50) were
more likely to have ER visits than were those who
demonstrated high adherence (PDC ≥ 80), (χ2 = 5.10,
p < 0.05). Similarly, members who were not persistent




Charlson Comorbidity Index* 1.1 (± 1.6)
1 [0 - 12]
Osteoporosis Drug Utilization in Pre-Period n,(%) 353 (46.4%)
Bisphosphonate n,(%) 283 (80.2%)
Calcitonin n,(%) 39 (11.0%)
Selective Estrogen Receptor Modulator (SERM) n,(%) 42 (11.9%)
Conjugated Estrogen n,(%) 22 (6.2%)
Fracture in the 6 Month Pre-Period n, (%) 386 (50.7%)
Fracture in the 12 Month Pre-Period n,(%) ** 443 (58.2%)
Comorbidity (Top 10 Identified) n, (%)†
Other disorders of bone and cartilage (733.) 752 (98.8%)
Essential hypertension (401.) 546 (71.7%)
Disorders of lipid metabolism (272.) 529 (69.5%)
General symptoms (780.) 474 (62.3%)
Other and unspecified disorders of back (724.) 402 (52.8%)
Symptoms involving respiratory system and other chest symptoms (786.) 391 (51.4%)
Other and unspecified disorders of joint (719.) 382 (50.2%)
Osteoarthritis and allied disorders (715.) 361 (47.44%)
Other disorders of soft tissues (729.) 333 (43.8%)
Cataract (366.) 281 (36.9%)
Post-Period Clinical Characteristics
Fracture in the 12 Month Post-Period n,(%) 222 (29.2%)
Time Between Index Date and First Fracture (Days)* 200 (± 81)
181 [91 - 364]
Proportion of Days Covered (PDC) Between Index Date and First Fracture* 0.46 (± 0.3)
0.38 [0.08 - 1.0]
Reached Part D Coverage Gap During 12 Month Follow-up Period n, (%) 586 (77%)
Out of Pocket Cost for All Prescription Claims During 12 Month Follow-up $2,082 (± $2,189)
Period* $991 [$30 - $10,894]
Out of Pocket Cost for Teriparatide Prescription Claims During 12 Month $1,247 (± $1,832)
Follow-up Period* $228 [$15 - $7,165]
*Mean (M), standard deviation (SD), median, [range].
** Data for fracture in 12 month pre-period were not available for the entire cohort.
†Based on the first 3 digits of ICD-9 CM code.
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than were the members who were persistent, (χ2 = 5.84,
p < 0.05).
With regard to total healthcare costs, the results in
Table 5 suggest differences in costs depending on the ad-
herence or persistence category that a patient belonged to.
The results of t-tests indicated significant differences in
total costs when comparisons were made between mem-
bers who were not persistent (i.e., discontinued therapy)and those that were persistent. Non-persistent members
had significantly lower mean healthcare costs (M= $16,341,
SD = $37,485) as compared to those who were persistent
(M= $21,046 SD= $13,560, t = 2.54, p < 0.05). ANOVA
pair-wise comparison revealed that members with PDC
<50 had lower total healthcare costs as compared to those
with PDC ≥ 80%. The average total costs during the follow
up period were lower in members demonstrating low ad-
herence as compared to those with high adherence,
Table 3 Total healthcare resource utilization and costs
Measure 12 month post period 24 month post period
Total Patients 761 272
Inpatient Hospitalization
Members with Hospitalization n,(%) 158 (20.8%) 85 (31.3%)
Hospitalizations Per Member** 0.4 (± 0.9) 0.7 (± 1.4)
0 [0 - 6] 0 [0 - 8]
Emergency Room Visits
Members with Visit n,(%) 236 (31.01%) 121 (44.49%)
Visits Per Member** 0.6 (± 1.6) 1.3 (± 3.0)
0 [0 - 30] 0 [0 - 42]
Outpatient Visits
Members with Visit n,(%) 760 (99.9%) 272 (100.0%)
Visits Per Member** 35. (± 33.5) 68.6 (± 61.7)
25 [0 - 320] 53 [9 - 698]
Pharmacy Claims
Members with Pharmacy Claim, n,(%) 761 (100.0%) 272 (100.0%)
Pharmacy Claims Per Member** 45.99 (± 31.9) 98.60 (± 65.9)
39 [1 - 214] 83 [4 - 366]
Total Healthcare Cost** $17,460 (± $33,437) $30,292 (± $67,230)
$10,896 [$1,097 - $758,916] $18,106 [$2,859 - $1,060,087]
Inpatient Hospitalization Cost** $4,585 (± $23,717) $8,978 (± $48,891)
$0 [$0 - $562,430] $0 [$0 - $774,152]
Emergency Room Visit Cost** $400 (± $2,433) $855 (± $4,312)
$0 [$0 - $62,129] $0 [$0 - $68,565]
Outpatient Cost** $5,713 (± $8,397) $9,673 (± $12,448)
$2,724 [$0 - $91,816] $6,067 [$0 - $144,264]
Pharmacy Cost** $6,762 (± $6,359) $10,787 (± $10,996)
$4,253 [$829 - $72,703] $6,343 [$855 - $73,434]
**Mean, standard deviation, median, [range].
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$15,528, SD = $37,713 versus (M = $21,033, SD =
$13,136, F = 3.35, p = 0.068).
Similar to observations of ER visits and total costs, the
results suggested significant differences in pharmacy costs
depending on adherence or persistence groupings. The
ANOVA pair-wise comparison revealed that the average
pharmacy costs of members with low adherence (M=
$4,361, SD = $5,344) were significantly lower than the
costs of members with high adherence (M= $13,472,
SD = $3,787, F = 411.35 p < 0.0001). In addition, t-test
results indicated significant differences in pharmacy costs
when comparisons were made between members whowere non-persistent and those that were persistent.
Non-persistent members had lower pharmacy costs
(M= $4,757, SD = $5,597) than their persistent counter-
parts (M= $13,187, SD = $3,935, t =22.57, p < 0.0001).
As shown in Table 6, similar adherence/persistence
groupings were evaluated for the 222 patients identified as
having a fracture during the 12-month follow-up period.
Among this group of patients, nearly 18% (39 patients)
were identified as being highly-adherent, and 19% (43
patients) were identified as being persistent with teripara-
tide therapy during the 12 month follow-up period. With
regard to fracture-related resource utilization and costs,
there were significant differences noted in total costs and
Table 4 Fracture-related healthcare resource utilization and costs†
Measure 12 month post period 24 month post period
Total Patients 222 134
Fracture-Related Inpatient Hospitalization
Members with Hospitalization n,(%) 21 (9.5%) 11 (8.2%)
Hospitalizations Per Member** 0.1 (± 0.4) 0.1 (± 0.4)
0 [0 - 2] 0 [0 - 2]
Fracture-Related Emergency Room Visits
Members with Visit n,(%) 35 (15.8%) 33 (24.6%)
Visits Per Member** 0.2 (± 0.5) 0.3 (± 0.6)
0 [0 - 3] 0 [0 - 3]
Fracture-Related Outpatient Visits
Members with Visit n,(%) 213 (95.9%) 126 (94%)
Visits Per Member** 4.1 (± 7.4) 4.6 (± 8.55)
2 [0 - 65] 2 [0 - 61]
Fracture-Related Pharmacy Claims
Pain Medications
Members with Pharmacy Claim n,(%) 161 (72.5%) 110 (82.1%)
Pharmacy Claims Per Member** 5.6 (± 7.7) 9.2 (± 11.9)
2 [0 - 43] 4 [0 - 55]
Osteoporosis Medications
Members with Pharmacy Claim n,(%)* 222 (100%) 134 (100%)
Pharmacy Claims Per Member** 5.8 (± 4.5) 10. (± 8.7)
4 [1 - 18] 6 [1 - 29]
Total Fracture-Related Cost** $6,198 (± $6,578) $8,389 (± $8,650)
$3,260 [$854 - $40,637] $3,944 [$854 - $47,033]
Inpatient Hospitalization Cost** $1,123 (± $4,506) $967 (± $3,582)
$0 [$0 - $37,355] $0 [$0 - $22,387]
Emergency Room Visit Cost** $35 (± $117) $100 (± $674)
$0 [$0 - $753] $0 [$0 - $7,692]
Outpatient Cost** $829 (± $2,297) $1,007 (± $3,128)
$179 [$0 - $23,383] $141 [$0 - $23,545]
Osteoporosis Medication Cost** $3,965 (± $3,640) $6,061 (± $6,737)
$2,459 [$779 - $14,910] $2,603 [$784 - $22,965]
Pain Medication Cost** $246 (± $758) $253 (± $605)
$24 [$0 - $6,276] $35 [$0 - $3,575]
† Among patients with a fracture.
*All patients with a fracture had an osteoporosis medication claim.
**Mean, standard deviation, median, [range].
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Table 5 Teriparatide utilization and overall utilization and costs in the 12 month follow-up period
Measure PDC* < 50% PDC 50% ≤ 80% PDC ≥ 80% Persistent Non-persistent
(low adherent) (moderately
adherent)
(highly adherent) (60 day gap)




116 (21.4%) 16 (28.1%) 26 (16.%) 31 (17.13%) 127 (21.9%)
Hospitalizations Per
Member**
0.4 (± 0.9) 0.5 (± 1.10) 0.2 (± 0.6) 0.3 (± 0.7) 0.4 (± 0.9)
0 [0 - 6] 0 [0 - 5] 0 [0 - 4] 0 [0 - 4] 0 [0 - 6]
Emergency Room Visits
Members with Visit n,(%) Δ ¥ 180 (33.27%) 17 (29.82%) 39 (23.93%) 43 (23.76%) 193 (33.28%)
Visits Per Member** 0.7 (± 1.8) 0.5 (± 0.8) 0.4 (± 1.1) 0.4 (± 1.04) 0.7 (± 1.7)
0 [0 - 30] 0 [0 - 3] 0 [0 - 9] 0 [0 - 9] 0 [0 - 30]
Outpatient Visits
Members with Visit n,(%) 540 (99.8%) 57 (100.0%) 163 (100.0%) 181 (100.0%) 579 (99.8%)
Visits Per Member** 35.4 (± 34.2) 39. (± 39.8) 32.3 (± 28.6) 32.7 (± 29.7) 35.7 (± 34.6)




541 (100.0%) 57 (100.0%) 163 (100.0%) 181 (100.0%) 580 (100.0%)
Pharmacy Claims Per
Member** † ‡
44.36 (± 31.01) 43.96 (± 28.70) 52.12 (± 35.06) 51.20 (± 34.72) 44.37 (± 30.79)
38 [1 - 214] 37 [4 - 127] 41 [6 - 186] 40 [6 - 186] 39 [1 - 214]













$4,897 (± $26,941) $8,448 (± $21,125) $2,198 (± $7,342) $2,535 (± $7,961) $5,224 (± $26,775)
$0 [$0 - $562,430] $0 [$0 - $123,486] $0 [$0 - $57,410] $0 [$0 - $57,410] $0 [$0 - $562,430]
Emergency Room Visit
Cost**
$465 (± $2,840) $330 (± $971) $211 (± $711) $205 (± $686) $461 (± $2,759)
$0 [$0 - $62,129] $0 [$0 - $5,486] $0 [$0 - $6,124] $0 [$0 - $6,124] $0 [$0 - $62,129]
Outpatient Cost** $5,806 (± $8,860) $6,439 (± $8,880) $5,151 (± $6,428) $5,118 (± $6,290) $5,899 (± $8,950)
$2,689 [$0 - $91,816] $2,724 [$93 - $44,149] $2,740 [$0 - $34,442] $2,583 [$0 - $34,442] $2,771 [$0 - $91,816]











* Proportion of days covered.
**Mean, standard deviation, median, [range].
† ANOVA pairwise comparison between PDC < 50% and PDC ≥ 80% groups, p < 0.05.
‡ t-test between ‘Persistent’ and ‘Non-Persistent’ (60 Day Gap) groups, p < 0.05.
Δ Chi-square comparison between PDC < 50% and PDC ≥ 80% groups, p < 0.05.
¥ Chi-square comparison between ‘Persistent’ and ‘Non-Persistent’ (60 Day Gap) groups, p < 0.05.
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Table 6 Teriparatide utilization and fracture-related utilization and costs in the 12 month follow-up period
Measure PDC* < 50% PDC 50% ≤80% PDC ≥ 80% Persistent Non-perstistent
low adherent moderately
adherent
highly adherent (60 day gap)




18 (10.7%) 1 (6.7%) 2 (5.1%) 2 (4.7%) 19 (10.6%)
Hospitalizations Per Member** 0.1 (± 0.4) 0.1 (± 0.3) 0.1 (± 0.2) 0. (± 0.2) 0.1 (± 0.4)
0 [0 - 2] 0 [0 - 1] 0 [0 - 1] 0 [0 - 1] 0 [0 - 2]
Fracture-Related Emergency Room Visits
Members with Visit, n (%) 31 (18.5%) 1 (6.7%) 3 (7.7%) 3 (6.98%) 32 (17.9%)
Visits Per Member** 0.2 (± 0.5) 0.1 (± 0.3) 0.1 (± 0.5) 0.1 (± 0.5) 0.2 (± 0.5)
0 [0 - 2] 0 [0 - 1] 0 [0 - 3] 0 [0 - 3] 0 [0 - 2]
Fracture-Related Outpatient Visits
Members with Visit, n (%) 160 (95.2%) 15 (100.%) 38 (97.4%) 42 (97.7%) 171 (95.5%)
Visits Per Member** 4.2 (± 7.96) 4.3 (± 5.14) 3.8 (± 5.48) 3.4 (± 5.21) 4.3 (± 7.83)





126 (75.0%) 11 (73.33%) 24 (61.54%) 27 (62.79%) 134 (74.86%)
Pharmacy Claims Per
Member**
5.5 (± 7.3) 6.1 (± 10.2) 5.7 (± 8.4) 5.5 (± 8.4) 5.6 (± 7.5)
2 [0 - 43] 2 [0 - 33] 2 [0 - 42] 2 [0 - 42] 2 [0 - 43]
Osteoporosis Medications
Members with Pharmacy Claim,
n (%)
168 (100.%) 15 (100.%) 39 (100.%) 43 (100.%) 179 (100.%)
Pharmacy Claims Per Member** † ‡ 4. (± 3.3) 9. (± 1.4) 12.5 (± 2.4) 12.2 (± 2.5) 4.3 (± 3.4)
3 [1 - 16] 9 [7 - 12] 13 [5 - 18] 12 [5 - 18] 3 [1 - 16]











Inpatient Hospitalization Cost** $1,325 (± $4,988) $830 (± $3,214) $366 (± $2,026) $332 (± $1,930) $1,313 (± $4,913)
$ [$0 - $37,355] $ [$0 - $12,449] $ [$0 - $12,585] $ [$0 - $12,585] $ [$0 - $37,355]
Emergency Room Visit Cost** $44 (± $132) $9 (± $36) $6 (± $24) $6 (± $23) $42 (± $129)
$0 [$0 - $753] $0 [$0 - $141] $0 [$0 - $128] $0 [$0 - $128] $0 [$0 - $753]
Outpatient Cost** $767 (± $1,903) $955 (± $1,538) $1,048 (± $3,716) $941 (± $3,545) $802 (± $1,892)
$159 [$0 - $12,380] $220 [$0 - $5,733] $215 [$0 - $23,383] $186 [$0 - $23,383] $176 [$0 - $12,380]
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Table 6 Teriparatide utilization and fracture-related utilization and costs in the 12 month follow-up period (Continued)
Pain Medication Pharmacy Cost** $216 (± $646) $77 (± $172) $440 (± $1,201) $404 (± $1,150) $208 (± $628)
$28 [$0 - $6,071] $11 [$0 - $662] $18 [$0 - $6,276] $14 [$0 - $6,276] $27 [$0 - $6,071]
* Proportion of days covered.
**Mean, standard deviation, median, [range].
† ANOVA pairwise comparison between PDC < 50% and PDC ≥ 80% groups, p < 0.05.
‡ t-test between ‘Persistent’ and ‘Non-Persistent’ (60 Day Gap) groups, p < 0.05.
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http://www.biomedcentral.com/1471-2474/14/4osteoporosis medication costs when low adherent patients
were compared those who were highly-adherent, and
when non-persistent members were compared with those
who were persistent. An ANOVA pair-wise comparison
revealed that the members with low adherence had, on
average, significantly lower total costs (M= $4,419, SD =
$6,018), than did members with high adherence (M=
$12,670, SD = $4,963 F = 63.254 p < 0.0001). In addition,
t-test results showed significantly lower total costs among
non-persistent members (M= $4,756, SD = $6,099), as
compared to the costs of persistent members (M =
$12,199, SD = $4,932 t =7.44, p < 0.0001).
With regard to osteoporosis medication costs, the average
costs during the follow up period were significantly lower
for members demonstrating low adherence (M= $2,068,
SD = $1,196), as compared to the higher costs for those
with high adherence (M= $10,810, SD = $1,250 F = 1662.62
p < 0.0001). In addition, there were significant differences in
osteoporosis medication costs when comparisons were
made between members who were non-persistent and
members who were persistent. These costs were signifi-
cantly lower for non-persistent members (M= $2,391, SD
= $1,746) than for persistent members (M= $10,516, SD
$1,520 t =28.06 p < 0.0001).Association between teriparatide adherence and
teriparatide persistence with fracture rates
Multivariate logistic regression analyses were used to
assess the associations between adherence and persist-
ence and the risk for a fracture in the 12-month period
following teriparatide initiation. As noted in Figures 2
and 3, two separate models were evaluated. The results
in Figure 2 describe the association of adherence and
fracture outcome, and those in Figure 3 depict the as-
sociation of persistence and fracture outcome. Age,
gender, geographic region, race/ethnicity, prior osteo-
porosis medication use, Deyo-Charlson comorbidity,
and prior fracture were covariates in both models.
As noted in Figures 2 and 3 and in Table 7, there were
no significant differences in fracture outcomes whether
or not patients were persistent in taking teriparatide
(OR 1.2, 95% CI 0.79, 1.82, NS), or regardless of their
adherence status (high versus low adherence [OR .81,
95% CI 0.515- 1.231, NS], and moderate versus lowadherence [OR .91.95% CI 0.479, 1.741, NS]). While
the regression models demonstrated no significant as-
sociation between teriparatide adherence or persistence
and 12-month fracture outcomes, the results indicated
that patients who had fractures in the 6 months before
initiation of TPTD were almost 3 times more likely to
have a fracture in the follow-up period (OR 2.9, 95% CI
2.1-4.1 p < 0.0001). Furthermore, only 28% of members
continued teriparatide use after their first fracture
episode.Discussion
This study explored the teriparatide utilization patterns
of patients with Medicare Advantage with Prescription
Drug (MAPD) coverage, excluding LIS beneficiaries,
who initiated teriparatide therapy, and the manner in
which those utilization patterns were associated with
fracture outcomes and healthcare utilization. While the
results suggested that there were no significant differ-
ences in fracture outcomes whether or not patients per-
sisted with taking the drug or whether or they were
adherent or not, this study identified specific patterns in
utilization and cost in this population.
The results of the adherence component of this study
support findings of other studies that have evaluated
osteoporosis therapies. Similar to previous studies, these
findings suggest that patients with osteoporosis tend to
have poor adherence to or persistence with prescribed
therapies, and that this poor adherence/persistence may
be associated with adverse clinical and economic out-
comes [24-27]. The results indicated that only 21% of
the study group was optimally adherent (PDC ≥ 80%) to
their teriparatide therapy at one year of follow up, and
that only 24% of patients continued to take the drug
during that same time period. Some studies have
reported higher rates of adherence with teriparatide
therapy 12 to 18 months following therapy initiation as
compared to this study’s findings [28-30]. Arden and
colleagues [29] reported an 87% persistence rate among
435 patients residing in the U.K., and Adachi et al [30]
reported an 82% adherence rate in a cohort of 116
patients participating in an 18-month, multi-center pro-
spective study of teriparatide adherence. In addition, a














































































Figure 2 Association of Teriparatide Adherence and 12-Month Fracture Risk*. Likelihood Ratio: (Χ2 = 55.16, 16 d.f. p < 0.0001), c statistic:
0.669. *Odds ratio and 95% confidence interval of experiencing a fracture during 12-month follow-up period based on adherence and adjusted
for age, gender, race/ethnicity, pre-period fractures, comorbidity, geographic region, and pre-period OP medication use.
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bined administrative claims of 3,587 commercial and
Medicare patients in the U.S. The difference in these
results may be due to the fact that the patient pool for
this study was comprised solely of Non-LIS Medicare
Part D beneficiaries, a large percentage of which had
reached the coverage gap in the 12 months following ini-
tiation of teriparatide. The lack of funds to cover the
cost of the medication once patients reach the coverage
gap could explain the observed lower rates of adherence.
A surprising finding in this study was that less than
half of the patient cohort (46.4%) had used another
osteoporosis medication in the 6 months prior to initiat-
ing teriparatide therapy. In lieu of choosing to take an
oral medication once weekly or monthly, a large per-
centage of patients initiated a once-daily injectable dos-
age form (teriparatide). Teriparatide is recommended for
patients at high risk of fracture, and so initiation in
treatment naïve patients does occur; however, common
clinical practice is for teriparatide to be utilized after
treatment failure on first line therapy. An additionalsurprising finding is the low incidence of prevalent frac-
ture (50%). With teriparatide’s indication for use, one
would have expected a much higher incidence of
patients with prevalent fracture. In clinical practice, teri-
paratide may often be utilized after treatment failure on
another osteoporosis medication [8,31]. This study’s ana-
lysis did not allow for the assessment of the level of se-
verity of osteoporosis in the patients, which presumably
would be more severe in this cohort based on the degree
of initiation of teriparatide. It is possible that some
health care providers may be prescribing teriparatide as
a first line agent based on a comprehensive assessment
of patients’ disease severity.
Interestingly, there was a low rate of persistence with
teriparatide after the first observed fracture. In fact, only
28% of patients in the study continued using the drug
after the first fracture; however, the underlying cause for
this non-persistence could not be investigated due to the
claims based structure of this study. It was not clear
whether the non-persistence was due to patient apathy
toward the benefit of their therapy, to patients
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ure, or due to prescribers deciding to discontinue the
therapy and opting for another treatment strategy.
The analyses evaluating the relationship between
utilization patterns (adherence or persistence) and
fracture-related utilization and costs revealed interesting
trends. The results suggested that patients who were
highly adherent or persistent with teriparatide therapy
had lower rates of emergency room utilization. among
patients who had poor adherence or non-persistence
with teriparatide therapy. Conversely, the patient groups
that were highly-adherent and/or were persistent with
teriparatide therapy had higher overall and pharmacy
costs than did their non-adherent/non-persistent coun-
terparts; almost 70% of the total costs of these highly-
adherent and persistent patients were attributable to
pharmacy expenses.
Our finding of a higher risk of fractures among patients
who had experienced fractures in the 6 months prior to
teriparatide initiation is consistent with previous stud-
ies of patients with osteoporosis [32-34]. Klotzbuecher



















































Figure 3 Association of Teriparatide Persistence and 12-Month Fractu
0.669. * Odds ratio and 95% confidence interval of experiencing a fracture
for age, gender, race/ethnicity, pre-period fractures, comorbidity, geograph
= non-persistent with teriparatide.histories of previous fractures at different sites have a
two-fold increased risk of having a future fracture [32].
Similarly, Haentjens and colleagues’ meta-analysis sug-
gested that prior wrist or spine fracture was associated with
an increased risk of future hip fracture in both men and
women [33]. Furthermore, Lindsay and colleagues’ analysis
of data from international trials of osteoporosis treatment
estimated that among older women who had a vertebral
fracture, 20% would experience another vertebral fracture
and 26% would incur a vertebral or non-vertebral fracture
within 12 months [34,35]. Our observations contribute to
this pool of information and support the need to closely
monitor and treat patients who have fractures in order to
mitigate the risk of future fracture, which is known to in-
crease morbidity and mortality rates [1,35,36]. Further re-
search is warranted in order to better understand and
reduce future risk, and to assess the efficacy of interven-
tions for reducing the incidence of fracture among high-
risk patients.
The present study has limitations that warrant consid-
eration when interpreting the findings. This is an obser-

























re Risk*†. Likelihood Ratio: (Χ2 = 54.83, 15 d.f. p < 0.0001), c statistic:
during 12-month follow-up period based on persistence and adjusted
ic region, and pre-period OP medication use. †Discontinue teriparatide
Table 7 Logistic regression of adherence and fracture risk* †
Variable Odds ratio 95% confidence interval P value
PDC (≥ 80% vs. <50%) 0.81 (0.515, 1.231) 0.48
PDC (≥ 50% ≤80% vs. < 50%) 0.91 (0.479, 1.741) 0.94
Age 1.00 (0.976, 1.016) 0.66
Gender (Female vs. Male) 1.37 (0.796, 2.368) 0.25
Race (Black vs. White) 1.41 (0.558, 3.538) 0.48
Race (Hispanic vs. White) 0.42 (0.048, 3.599) 0.29
Race (Other vs. White) 1.80 (0.689, 4.703) 0.22
Fracture in 6 Month Period before Initiating Teriparatide 2.93 (2.084, 4.122) <.0001
Charlson Comorbidity 0.96 (0.861, 1.07) 0.46
Geographic Region (West vs. Northeast) 1.38 (0.347, 5.513) 0.99
Geographic Region (Southeast vs. Northeast) 2.07 (0.566, 7.531) 0.05
Geographic Region (Midwest vs. Northeast) 1.29 (0.341, 4.889) 0.76
Bisphosphonate Use 1.04 (0.738, 1.469) 0.82
Calcitonin Use 0.62 (0.283, 1.378) 0.24
Selective Estrogen Receptor Modulator Use 1.16 (0.551, 2.433) 0.70
Estrogen Use 0.61 (0.197, 1.891) 0.39
* Results of multivariate logistic regression analyses, with ‘Fracture in 12 Month Post-Period’ as the outcome variable.
† Among patients with a fracture.
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with clinical and economic outcome variables; the
results do not show causal relationships among vari-
ables. In addition, other limitations common to studies
using administrative claims data apply to this study.
These include threats to validity presented by missing
data, errors in claims coding, a lack of data on indirect
costs, as well as unmeasured factors which may be asso-
ciated with adherence. For example, the study did not
control for potentially confounding factors such as pa-
tient health beliefs and provider-patient communication,
which could have obscured the relationships of adher-
ence and persistence with the clinical and economic out-
comes. Additionally, the observations around prevalent
fractures as well as use among treatment naïve patients
makes it difficult to extrapolate these data to one better
defined by the approved indication for use. Although
multivariate regression modeling is used in the present
study to reduce selection bias and control for confound-
ing, it can only reduce bias caused by measured covari-
ates; it cannot reduce bias caused by unmeasured
covariates. Other study limitations may be the results of
the criteria used to define the sample as well as those
used to evaluate fracture outcomes. Patients who were
LIS beneficiaries during the study period (560 patients)
were excluded from the sample. Had those patients been
included, the sample size would have been much larger,
potentially increasing the generalizability of the study
findings and permitting comparisons of the characteris-
tics of the present study’s patients with those of the LISgroup. With regard to the assessment of fractures, the
present study’s analysis excluded fractures occurring
within the first 90 days of teriparatide initiation, similar
to approaches used in previous studies (e.g. 180 days
used by Halpern et al. [27] so as to allow sufficient time
for treatment effects to begin [37]) and assessed
adherence and fracture outcomes concurrently. Some
researchers posit that these approaches may give rise to
inaccuracies in determining the association of adherence
with fracture outcomes, and suggest that it is advisable
to include an assessment of adherence prior to the oc-
currence of a fracture [38,39]. Finally, the current study
uses data from a single large national health insurance
company exclusively, thus the results might not be
generalizable to the general U.S. population.
Conclusions
In summary, the study’s findings suggest a need to better
understand and improve adherence to teriparatide in Medi-
care Part D beneficiaries with osteoporosis. The results
were inconclusive in terms of the exact relationship be-
tween poor adherence and negative outcomes such as
increased utilization of ER visits and fracture rates. The
results demonstrated a trend for highly-adherent patients
to have higher healthcare costs most likely due to
significantly higher pharmacy expenditures. Furthermore,
patients who persisted with teriparatide use had signifi-
cantly higher healthcare costs than patients who were non-
persistent with therapy. The results also suggested that
emergency room utilization was higher among non-
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that effect cannot be definitively tied to teriparatide use. In
addition, the study’s results highlight the importance of
monitoring clinical outcomes of patients who have fractures
in order to reduce the risk of future fractures. Future stud-
ies could evaluate the underlying factors contributing to
higher healthcare utilization rates as well as the factors
underlying more favorable outcomes such as lower
utilization rates (for example, regression analyses with ER
visits and inpatient hospitalizations as outcome variables).
Methods
Study design
This retrospective cohort study was designed to analyze
the medical and pharmaceutical claims data of 761
Medicare members who had both pharmacy and medical
benefits. The study’s goals were to describe the clinical
and economic outcomes of Medicare Part D beneficiar-
ies newly started on teriparatide, and to examine the
relationships of adherence and persistence with health-
care resource use and fracture outcomes. The data
sources for this study included member enrollment,
medical, and pharmacy data generated from the claims
database of a large national healthcare provider. This
study was part of a larger protocol, which was approved
by the Western Institutional Review Board.
Selection of participants
The patient sample was drawn from a cohort of patients
from a large national health insurance company who
were enrolled in the Medicare Advantage with Prescrip-
tion Drug coverage (MAPD) plan. In addition, patients
included in the study were Medicare Part D recipients,
aged 18 to 89 years old, and not members of the Low In-
come Subsidy program (LIS) for Medicare Part D at any
time during the study period (LIS is a Medicare program
which provides additional prescription drug coverage to
low income Medicare Part D beneficiaries). LIS mem-
bers were excluded from the study because they were
more likely to be buffered from the cost-sharing effects
of the Medicare Part D plan. Study participants had at
least one pharmacy claim for teriparatide (Generic Prod-
uct Identifier [GPI] code 30044070) during the identifi-
cation period of January 1, 2008 to December 31, 2009.
The date of the first pharmacy claim for teriparatide was
considered the index date. In addition, participants had
at least 18 months of total enrollment, that is, at least 6
months prior to the index date (baseline period) and at
least 12 months post the index date (follow-up period).
The patients’ baseline demographics, pre-existing frac-
ture rates, medication use, and comorbidities in the
baseline period were evaluated. Clinical and economic
outcomes were assessed during the 1-12 months post-
index and the 1-24 months post–index.Primary outcome measures
Healthcare resource utilization
The quantity of both inpatient and outpatient services
received, as well as all-cause health care resource
utilization in the claims data, were measured during the
12 and 24 month follow-up periods. This included out-
patient (physician office visits, procedures and tests), in-
patient hospitalizations, emergency room (ER) visits, and
pharmaceutical claims.
Healthcare costs
Total overall costs and total fracture-related health care
costs (reimbursements and co-pays) associated with the
aforementioned health care resource utilizations, were
measured during the follow-up period. All pharmacy
and medical claims for members were examined during
the follow-up period to assess total out of pocket phar-
macy and medical spending. Costs were adjusted to
2010 dollars using the U.S. Bureau of Labor Statistics’
Consumer Price Index for Medical Care. Fracture-
related services were characterized by an ICD-9 code
according to the criteria used to identify fractures, which
are outlined in the fracture section below.
Fractures occurring in the 12 and 24-month follow-up
period
Fractures occurring in the follow-up period were assessed,
with the exception of fractures occurring within the first
90 days following teriparatide initiation, as those fractures
could not be reliably associated with osteoporosis treat-
ment. The following criteria were used to identify the
presence of fractures:
Fracture inclusion criteria Fractures were included if
they were identified by the ICD-9-CM codes for frac-
tures likely related to osteoporosis 813 to 814 (radius,
ulna, and carpal fractures), 805 (vertebral fracture with-
out spinal cord injury), 807.0 to 807.4 (rib fractures), 820
to 821 (femur fracture), or 808 to 809 (pelvic fracture
and ill-defined fracture of the trunk). Also included
were first fractures at any site identified by primary or
secondary diagnosis (ICD 9) indicating a fracture on a
non-diagnostic claim of inpatient, emergency room, or
outpatient service, and ICD 9 codes (733.1) for patho-
logic fracture not related to cancer or Paget’s disease.
Fracture exclusion criteria Fractures were excluded if
they were identified by ICD 9 diagnosis codes associated
with a malignant neoplasm (excluding non-melanoma
skin cancer) or a benign tumor of bone in the 12
months before or in the 6 months following the date of
the fracture, and if there was evidence for a malignancy
that had diagnosis codes only for a history of cancer
(ICD-9 V10). Pathological fractures were excluded if the
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of the fracture diagnosis. Evidence of traumatic fracture
(for example, fractures that were the result of a motor
vehicular or pedal cycle accident), fractures accompan-
ied by codes suggesting 3 or more simultaneous frac-
tures, and open fractures, were excluded because they
were likely to be the result of trauma rather than
osteoporosis.
Independent variables and covariates
Covariates
Age, gender and race/ethnicity Age, gender, and race/
ethnicity were captured from enrollment data. Patient
age was measured as of the index date.
Geographic region Geographic region was based on the
patient’s state of residence on the index date. Regional
assignment (Northeast, Midwest, South, and West) was
based on the U.S. Census Bureau assignment of states to
a geographic region.
Osteoporosis medication utilization This was evalu-
ated using the pharmacy claims for each member during
the baseline and follow-up periods. Utilization was based
on receiving one or more paid pharmacy claims where
the MediSpan© Generic Product Identifier (GPI) code
was for a bisphosphonate (GPI-6 30.04.20), calcitonin
(GPI-6 30.40.30), selective estrogen modulator (SERM)
(GPI-8 30.05.30.60), or estrogen replacement therapy
(GPI-4 24.99, 55.35).
The Deyo-Charlson comorbidity index (DCI) This
index was used to assess the cohort’s baseline comorbid
conditions. It uses 17 categories of comorbidity to calcu-
late a score that reflects cumulative increased likelihood
of one-year mortality. It is based on ICD-9 diagnoses
and procedure codes, and their associated weights. The
DCI score can range from 0 to 33. Claims with the spe-
cified codes are used in the calculation of the DCI if they
meet the following criteria (1) Used on an inpatient
hospitalization or (2) Two or more claims 30 days apart
on separate outpatient claims [40].
Prior fracture Fractures episodes occurring in the ‘pre’
period (6 months before initiation of teriparatide) were
also assessed using the aforementioned fracture inclu-
sion/exclusion criteria for identification of fractures,
described above.
Independent variables
Medication adherence – proportion of days covered (PDC)
Medication adherence was calculated as the proportion of
days covered (PDC). PDC was measured as a 12 month
fixed follow-up period from the index date. The PDC wascalculated as a percentage, which is equal to the number of
days with teriparatide on hand divided by the number of
days in the period. A PDC of 100 will equal 100% adher-
ence. The number of days with teriparatide on hand was
calculated using a set of rules to avoid double-counting
covered days when prescription fills for teriparatide overlap,
as opposed to summing the day supply for all teriparatide
prescriptions received during the period. Summing the
days’ supply is used in the calculation of a Medication Pos-
session Ratio (MPR), another adherence measure. This
method can overestimate the level of adherence during a
fixed period of follow-up (i.e. 12 months, as in this study),
especially if early refilling of prescriptions by the patient fre-
quently occurs. ‘Appropriate’ or optimal medication usage
was defined as having a PDC ≥ 80% and ‘inappropriate’ or
suboptimal medication usage was defined as having a PDC
of <80%. For the purpose of comparison, PDC was divided
into the 3 categories of high, moderate and low. ‘High’ was
defined as a PDC greater than or equal to 80% (PDC
≥80%), ‘moderate’ was described as a PDC greater than or
equal to 50% but less than 80% (50% ≤ PDC < 80%), and
‘low’ was a PDC less than 50% (PDC < 50%).Therapy non-persistence
Non-persistence with therapy (discontinuation) was
defined as at least a 60-day gap in any subsequent teri-
paratide medication claim. The discontinuation date was
defined as the date of the last prescription claim prior to
the refill gap being exceeded, plus the day of supply of that
claim. The refill gap was calculated using a procedure to
avoid double-counting covered days when prescription
fills for teriparatide overlap [41].
Other variables
Pain medication utilization
This was evaluated using the pharmacy claims for each
member during the follow-up periods. Utilization was
based on receiving one or more paid pharmacy claims
where the GPI was for an opioid or non-steroidal
anti-inflammatory drug (NSAID) therapy (GPI code
661000xx).
Analysis plan
A sample attrition table was produced to identify how
many members were removed from the sample due to the
specified exclusion/inclusion criteria. Descriptive statistics
(mean, standard deviation and range for continuous vari-
ables, as well as percentages for dichotomous variables)
were produced to summarize the group’s demographic and
clinical characteristics. Counts were provided (mean, me-
dian, standard deviation, and range) to summarize the over-
all and osteoporosis-related resource utilization and cost
patterns for members with at least 12 months of post-
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measures were calculated for members with 24-months of
post-period follow-up (i.e., months 1-24, post index). Simi-
lar counts were produced and then grouped according to
patients’ PDC status for comparison of 12 and 24 month
outcomes. PDC calculations were used as predictor vari-
ables in analyses of 12 and 24 month clinical and economic
outcomes. We summarized the 12 and 24 month overall
and osteoporosis-related resource utilization and cost pat-
terns between the groups of members based on their
utilization of teriparatide. Chi Square analyses and ANOVA
pairwise comparisons were performed to determine
whether there were significant differences in healthcare
utilization and costs for patients with high adherence (PDC
≥80%) as compared to those with low adherence (PDC <
50%). T-Tests were used to assess significant differences in
utilization and costs for patients who were persistent with
therapy as compared to those who were non-persistent.
Multivariate logistic regression analyses were used to as-
sess the association between adherence/persistence and
fracture outcomes. Two regression models were evaluated
to separately assess the associations of a) adherence and b)
persistence, on fracture occurrence at follow-up. In the first
model, adherence status was divided into the categories of
high versus low (PDC < 80% vs. PDC < 50%), or moderate
versus low (50% ≤ PDC < 80% vs. PDC < 50%). For the sec-
ond model, persistence with teriparatide was measured as
dichotomous variable (non-persistence with treatment or
persistence). In both models the dependent variable was
the occurrence of a fracture during the 12-month follow-up
period. Age, gender, geographic region, race/ethnicity, prior
osteoporosis medication use, Deyo-Charlson comorbidity,
and prior fracture were included as covariates in the mod-
els. All analyses were performed using SAS Enterprise
Guide 4.2 statistical software (Cary, North Carolina, USA).
The significance level was set at < 0.05 for all statistical
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